Oncology Pipelines: Is the Future Targeted Therapy?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Cancer Therapy Today and Tomorrow
• Targeted Therapy-Hitting Cancer Where it Hurts
• Leaders in Oncology
• Today' s Reality-Diffi culties in Developing Targeted Therapies
  • Toxicities and Black Box Warnings
  • Personalized Medicine
    • Murphy' s Law in Effect
    • Key Products in Development
  • AstraZeneca' s Initial Disappointment Gives Rise to Changes
  • Bristol-Myers Squibb Expands into Biologics
  • Exelixis Engages in Aggressive Drug Discovery and Development
    • Third-Party Clinical Financing Vehicle
    • Small-Molecule Kinase Inhibitors
  • Genentech/Roche Lead the Way with Oncology Biologics
  • Genmab Makes Waves with Largest European Product Deal Ever
  • GlaxoSmithKline Advances into Herceptin' s Space in Breast Cancer
  • ImClone Faces Ongoing Strife but Boasts a Legitimate Blockbuster
  • ImmunoGen Innovates with Armed Antibody Technology
  • Novartis Banks on Small-Molecule Kinase Inhibitors
  • Pfi zer Moves Beyond Historical Reliance on Small-Molecule Drug Technologies
• Waves of the Future
  • Somber Refl ection on Human Genome Sequencing
  • Mainstay Cancer Treatment Circa 2015
  • Personalized Targeted Therapies
  • Tomorrow' s RNA Targeted Therapies

Spectrum Expert Commentaries:

• “Targeted Oncology Therapy: Trend Toward Personalized Treatment,” by David Z. Chang, M.D., Ph.D., Gastrointestinal Medical Oncology & Immunology, The University of Texas, M.D. Anderson Cancer Center
• “The Potential of MicroRNA Modulators as Targeted Oncology Therapies,” by Fabricio F. Costa, Ph.D., Cancer Biology and Epigenomics Program, Children' s Memorial Research Center, Northwestern University' s Feinberg School of Medicine, and Thomas Wurdinger, Ph.D., Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School

Tables:

• 1. Amgen' s Targeted Oncology Pipeline-Select Products, 2007
• 2. AstraZeneca' s Targeted Oncology Pipeline-Select Products, 2007
• 3. Bristol-Myers Squibb' s Targeted Oncology Pipeline-Select Products, 2007
• 4. Exelixis' s Targeted Oncology Pipeline-Select Products, 2007
• 5. Genentech and Roche' s Combined Targeted Oncology Pipeline-Select Products, 2007
• 6. Genmab' s Targeted Oncology Pipeline-Select Products, 2007
• 7. GlaxoSmithKline' s Targeted Oncology Pipeline-Select Products, 2007
• 8. ImClone' s Targeted Oncology Pipeline-Select Products, 2007
• 9. ImmunoGen' s Targeted Oncology Pipeline-Select Products, 2007
• 10. Novartis' s Targeted Oncology Pipeline-Select Products, 2007
• 11. Pfi zer' s Targeted Oncology Pipeline-Select Products, 2007

Figures:

• 1. Leading Sites of New Cancer Cases and Deaths-2007 Estimates
• 2. Considerations for Successful Anticancer Drug Development
• 3. Best-Selling Oncology Products, 2006 and 2012
• 4. Leading Oncology Franchises-Key Products, 2006
• Expert Commentary. Epidermal Growth Factor Receptor Targeted Drugs